Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

BLOGS
Home›BLOGS›Besponsa (inotuzumab ozogamicin) a new FDA approved drug

Besponsa (inotuzumab ozogamicin) a new FDA approved drug

By admin
September 14, 2017
704
0
Share:

Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC).

Besponsa is specifically indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Besponsa is supplied as a solution for intravenous injection. The recommended dose schedule is as follows:

For the first cycle: the recommended total dose of Besponsa for all patients is 1.8 mg/m2 per cycle, administered as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity.

For subsequent cycles: In patients who achieve a CR or CRi, the recommended total dose of Besponsa is 1.5 mg/m2per cycle, administered as 3 divided doses on Day 1 (0.5 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. OR  In patients who do not achieve a CR or CRi, the recommended total dose of Besponsa is 1.8 mg/m2 per cycle given as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. Patients who do not achieve a CR or CRi within 3 cycles should discontinue treatment.

For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with Besponsa is 2 cycles. A third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles.

For patients not proceeding to HSCT, additional cycles of treatment, up to a maximum of 6 cycles, may be administered.

Please see drug label for specific dose modifications based on toxicities.

Clinical Results

FDA Approvals

The FDA approval of Besponsa was based on a randomized trial of 326 patients with relapsed or refractory B-cell ALL who had received one or two prior treatments. Patients were randomized to receive treatment with Besponsa or an alternative chemotherapy regimen. The trial measured the percentage of patients with no evidence of disease and full recovery of blood counts after treatment (complete remission or CR). Of the 218 evaluated patients, 35.8 percent who received Besponsa experienced CR for a median 8.0 months; of the patients who received alternative chemotherapy, 17.4 percent experienced CR for a median 4.9 months.

Side Effects

Adverse effects associated with the use of Besponsa may include, but are not limited to, the following:

  • thrombocytopenia
  • neutropenia
  • infection
  • anemia
  • leukopenia
  • fatigue
  • hemorrhage
  • pyrexia
  • nausea
  • headache
  • febrile neutropenia
  • transaminases increased
  • abdominal pain
  • gamma-glutamyltransferase increased
  • hyperbilirubinemia

The Besponsa drug label includes a boxed warning that severe liver damage (hepatotoxicity), including blockage of veins in the liver (veno-occlusive disease [VOD] or sinusoidal obstruction syndrome), occurred in some patients who took Besponsa.

Mechanism of Action

Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22.  The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of inotuzumab ozogamicin is due to the binding of the ADC to CD22-expressing tumor cells, followed by internalization of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin dimethylhydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death.

 

Tagsantibody-drug conjugate.B-cell precursor acute lymphoblastic leukemiahematopoietic stem cell transplant
Previous Article

Useful websites and online educational support.

Next Article

DUAL CONTROL OF PHARMACY EDUCATION IN INDIA

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0
User Avatar

admin

Related articles More from author

  • BLOGS

    New malaria drug AQ-13 found effective in human trial

    September 14, 2017
    By admin
  • Phama news

    Pharmacists are not eligible for certificate program of community health

    December 22, 2019
    By admin
  • BLOGS

    Can biotin manipulate lab test

    August 28, 2018
    By admin
  • BLOGS

    US FDA approves first biosimilar for certain breast and stomach cancers treatment

    December 4, 2017
    By admin
  • BLOGS

    IPC 2017 : Indian Pharmaceutical Congress

    September 19, 2017
    By admin
  • Phama news

    ASTHMA

    January 10, 2020
    By Sriram Nagarajan

Leave a reply Cancel reply

You may interested

  • Educational news

    Facing criticism, govt to go slow on replacing UGC with a new body

  • BLOGS

    Membrane vacuum cleaner as a new target for antibiotic resistance.

  • Phama news

    CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  • LATEST REVIEWS

  • TOP REVIEWS

  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • August 3, 2023

    List of UGC declared 20 universities as fake, not authorised to award degrees.

  • July 28, 2023

    Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • May 24, 2021

    LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

  • October 20, 2020

    List of UGC Approved journals 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

Latest Comments

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC declared 20 universities as fake, not authorised to award degrees.

    By mythandintegrity
    August 3, 2023
  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

    By mythandintegrity
    July 28, 2023
  • LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

    By admin
    May 24, 2021
  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.